Abstract:Systematically discovering protein-ligand interactions across the entire human and pathogen genomes is critical in chemical genomics, protein function prediction, drug discovery, and many other areas. However, more than 90% of gene families remain "dark"-i.e., their small-molecule ligands are undiscovered due to experimental limitations or human/historical biases. Existing computational approaches typically fail when the dark protein differs from those with known ligands. To address this challenge, we have developed a deep learning framework, called PortalCG, which consists of four novel components: (i) a 3-dimensional ligand binding site enhanced sequence pre-training strategy to encode the evolutionary links between ligand-binding sites across gene families; (ii) an end-to-end pretraining-fine-tuning strategy to reduce the impact of inaccuracy of predicted structures on function predictions by recognizing the sequence-structure-function paradigm; (iii) a new out-of-cluster meta-learning algorithm that extracts and accumulates information learned from predicting ligands of distinct gene families (meta-data) and applies the meta-data to a dark gene family; and (iv) a stress model selection step, using different gene families in the test data from those in the training and development data sets to facilitate model deployment in a real-world scenario. In extensive and rigorous benchmark experiments, PortalCG considerably outperformed state-of-the-art techniques of machine learning and protein-ligand docking when applied to dark gene families, and demonstrated its generalization power for target identifications and compound screenings under out-of-distribution (OOD) scenarios. Furthermore, in an external validation for the multi-target compound screening, the performance of PortalCG surpassed the rational design from medicinal chemists. Our results also suggest that a differentiable sequence-structure-function deep learning framework, where protein structural information serves as an intermediate layer, could be superior to conventional methodology where predicted protein structures were used for the compound screening. We applied PortalCG to two case studies to exemplify its potential in drug discovery: designing selective dual-antagonists of dopamine receptors for the treatment of opioid use disorder (OUD), and illuminating the understudied human genome for target diseases that do not yet have effective and safe therapeutics. Our results suggested that PortalCG is a viable solution to the OOD problem in exploring understudied regions of protein functional space.

Genome-wide Prediction of Small Molecule Binding to Remote Orphan Proteins Using Distilled Sequence Alignment Embedding

MSA-Regularized Protein Sequence Transformer toward Predicting Genome-Wide Chemical-Protein Interactions: Application to GPCRome Deorphanization

DeepREAL: A Deep Learning Powered Multi-scale Modeling Framework Towards Predicting Out-of-distribution Receptor Activity of Ligand Binding

DeepREAL: a deep learning powered multi-scale modeling framework for predicting out-of-distribution ligand-induced GPCR activity

End-to-end sequence-structure-function meta-learning predicts genome-wide chemical-protein interactions for dark proteins

Decrypting orphan GPCR drug discovery via multitask learning

Improving the generalizability of protein-ligand binding predictions with AI-Bind

DEELIG: A Deep Learning Approach to Predict Protein-Ligand Binding Affinity

Deep Learning-Based Modeling of Drug–Target Interaction Prediction Incorporating Binding Site Information of Proteins

Exploration of Dark Chemical Genomics Space via Portal Learning: Applied to Targeting the Undruggable Genome and COVID-19 Anti-Infective Polypharmacology

DeepGS: Deep Representation Learning of Graphs and Sequences for Drug-Target Binding Affinity Prediction

Synergistic Application of Molecular Docking and Machine Learning for Improved Binding Pose

State-specific protein-ligand complex structure prediction with a multi-scale deep generative model

AI-Bind: Improving Binding Predictions for Novel Protein Targets and Ligands

Enhancing Drug-Target Binding Affinity Prediction through Deep Learning and Protein Secondary Structure Integration

Enhancing generalizability and performance in drug–target interaction identification by integrating pharmacophore and pre-trained models

A new paradigm for applying deep learning to protein–ligand interaction prediction

A deep learning method for drug-target affinity prediction based on sequence interaction information mining

PharML.Bind: Pharmacologic Machine Learning for Protein-Ligand Interactions

DeepLPI: a novel deep learning-based model for protein–ligand interaction prediction for drug repurposing

Corresponding Projections for Orphan Screening